Frontiers in Medicine (May 2022)
Serum Metabolomics Benefits Discrimination Kidney Disease Development in Type 2 Diabetes Patients
- Xiaofeng Peng,
- Xiaofeng Peng,
- Xiaofeng Peng,
- Xiaofeng Peng,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xiaoyi Wang,
- Xue Shao,
- Xue Shao,
- Xue Shao,
- Xue Shao,
- Yucheng Wang,
- Yucheng Wang,
- Yucheng Wang,
- Yucheng Wang,
- Shi Feng,
- Shi Feng,
- Shi Feng,
- Shi Feng,
- Cuili Wang,
- Cuili Wang,
- Cuili Wang,
- Cuili Wang,
- Cunqi Ye,
- Cunqi Ye,
- Cunqi Ye,
- Cunqi Ye,
- Cunqi Ye,
- Jianghua Chen,
- Jianghua Chen,
- Jianghua Chen,
- Jianghua Chen,
- Hong Jiang,
- Hong Jiang,
- Hong Jiang,
- Hong Jiang
Affiliations
- Xiaofeng Peng
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Xiaofeng Peng
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Xiaofeng Peng
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Xiaofeng Peng
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Xiaoyi Wang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Xiaoyi Wang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Xiaoyi Wang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Xiaoyi Wang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Xiaoyi Wang
- Department of Nephrology, The First Affiliated Hospital of Huzhou Teachers College, The First People's Hospital of Huzhou, Huzhou, China
- Xue Shao
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Xue Shao
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Xue Shao
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Xue Shao
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Yucheng Wang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Yucheng Wang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Yucheng Wang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Yucheng Wang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Shi Feng
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Shi Feng
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Shi Feng
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Shi Feng
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Cuili Wang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Cuili Wang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Cuili Wang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Cuili Wang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Cunqi Ye
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Cunqi Ye
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Cunqi Ye
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Cunqi Ye
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Cunqi Ye
- Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, China
- Jianghua Chen
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Jianghua Chen
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Jianghua Chen
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Jianghua Chen
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- Hong Jiang
- Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- Hong Jiang
- Key Laboratory of Kidney Disease Prevention and Control Technology, Hangzhou, China
- Hong Jiang
- Institute of Nephropathy, Zhejiang University, Hangzhou, China
- Hong Jiang
- Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, China
- DOI
- https://doi.org/10.3389/fmed.2022.819311
- Journal volume & issue
-
Vol. 9
Abstract
BackgroundDiabetic kidney disease (DKD) is the primary cause of end-stage renal disease, raising a considerable burden worldwide. Recognizing novel biomarkers by metabolomics can shed light on new biochemical insight to benefit DKD diagnostics and therapeutics. We hypothesized that serum metabolites can serve as biomarkers in the progression of DKD.MethodsA cross-sectional study of 1,043 plasma metabolites by untargeted LC/MS among 89 participants identified associations between proteinuria severity and metabolites difference. Pathway analysis from differently expressed metabolites was used to determine perturbed metabolism pathways. The results were replicated in an independent, cross-sectional cohort of 83 individuals. Correlation and prediction values were used to examine the association between plasma metabolites level and proteinuria amount.ResultsDiabetes, and diabetic kidney disease with different ranges of proteinuria have shown different metabolites patterns. Cysteine and methionine metabolism pathway, and Taurine and hypotaurine metabolism pathway were distinguishable in the existence of DKD in DC (diabetes controls without kidney disease), and DKD with different ranges of proteinuria. Two interesting tetrapeptides (Asn-Met-Cys-Ser and Asn-Cys-Pro-Pro) circulating levels were elevated with the DKD proteinuria progression.ConclusionsThese findings underscore that serum metabolomics provide us biochemical perspectives to identify some clinically relevant physiopathologic biomarkers of DKD progression.
Keywords
